Dossier assessment
Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with type 2 diabetes mellitus
Added benefit not proven for any of the 5 subindications specified by the G-BA because the drug manufacturer did not address these research questions in its dossier
Additional information
Federal Joint Committee (G-BA)
2019-12-19 A G-BA decision was published.
Project details
- Project no.
- A19-53
- Commission
- Commission awarded on 18.06.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Dapagliflozin (type 2 diabetes mellitus) - Addendum to Commission A19-53
Status: Commission completed
-
Dossier assessment
Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed
-
Dossier assessment
Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed